Duvortuxizumab

Edit links
Source: Wikipedia, the free encyclopedia.
Duvortuxizumab
humanized hybrid (mouse/human)
TargetCD19
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC4850H7485N1305O1487S35
Molar mass108989.98 g·mol−1

Duvortuxizumab (

B-cell malignancies.[2]

This drug was developed by Janssen Global Services.[3]

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. doi:10.1158/1538-7445.AM2017-3636
    .
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Duvortuxizumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Duvortuxizumab&oldid=1160196363"